Next-Generation CAR T Therapy Obe-cel Receives FDA Approval for ALL (Acute Lymphoblastic Leukemia)

On November 8, 2024, the FDA (United States Food and Drug Administration) approved obecabtagene autoleucel, or obe-cel (AUTO1, Autolus Therapeutics), for adults with relapsed or refractory (recurrent or treatment-resistant) B-cell acute lymphoblastic leukemia (ALL). This innovative CD19-targeted CAR T-cell therapy is considered a promising option for patients with serious cancers such as ALL that are resistant to conventional approaches.

Next-Generation CAR T Therapy

With its autokinetic design, obe-cel is intended to minimize overstimulation of active T cells and increase their long-term persistence. This feature aims to reduce the risk of T-cell exhaustion. Approval was based on efficacy and safety results from the open-label, single-arm FELIX study.

Initial findings from FELIX were presented at the 2023 American Society of Clinical Oncology (ASCO) meeting, while an updated analysis of phase 1b/2 data was presented at the 2023 American Society of Hematology conference.

• Related topic: What Is Leukemia and What Are Its Types? What Are Overall Survival Rates by Age?

How Does It Differ from Previous CAR T-Cell Therapies?

As a CD19-targeted CAR T-cell therapy, obe-cel stands out for its innovative design. It contains a specialized binding region with fast off-rate kinetics for CD19. This feature allows T cells to disengage rapidly from the target antigen, aiming to reduce excessive activation and associated adverse effects. In addition, these fast off-rate kinetics prevent T-cell exhaustion, providing long-term activity and persistence.

CD19 is a protein on the surface of B lymphocytes that plays a role in their activation, differentiation, and proliferation. It is targeted in cancer treatment because CD19 is consistently expressed in B-cell malignancies (such as acute lymphoblastic leukemia and certain lymphomas), allowing cancerous B cells to be specifically recognized and destroyed.

This design of obe-cel helps reduce adverse effects such as cytokine release syndrome (CRS) and neurotoxicity seen with conventional CAR T-cell therapies. In FELIX, grade 3 or higher CRS occurred in 2.4% of patients treated with obe-cel, while grade 3 or higher neurotoxicity occurred in 7.1%. These low rates indicate an improved safety profile for obe-cel.

Key Findings: Response Rates and Safety Profile

According to the pooled analysis of FELIX,

• 77% of patients treated with obe-cel achieved a complete response (CR) or complete response without hematologic recovery.
• Among the 124 treated patients, median follow-up was 11 months and the complete response rate was 57%.
• 96% of patients achieved minimal residual disease-negative status, and median response duration had not yet been reached.

Safety data showed grade 3 or higher cytokine release syndrome in only 2.4% of patients and immune effector cell-associated neurotoxicity syndrome in 7.1%. These low rates indicate a lower toxicity profile for obe-cel.

Study Details and Administration Protocol

FELIX included patients aged 18 and older with relapsed/refractory B-cell ALL and a performance status of 0 or 1. Patients received lymphodepletion with fludarabine and cyclophosphamide before obe-cel therapy. The target CAR T-cell dose was 410 million cells, with the infusions split between days 1 and 10 according to the bone marrow blast percentage before lymphodepletion.

Treatment responses were particularly effective in patients with a low leukemia burden. Of 10 patients who were minimal residual disease-positive before treatment, 9 achieved a complete response and all became minimal residual disease-negative. Median response duration had not been reached in this group, and no severe cytokine release syndrome (CRS) occurred. Among 27 patients in morphologic remission during lymphodepletion, 89% achieved a complete response and the minimal residual disease-negative rate was 100%. No severe CRS or immune effector cell-associated neurotoxicity syndrome occurred in this group either.

Long-Term Outcomes and Survival Rates

Additional data presented at the 2024 ASCO meeting showed a 12-month event-free survival rate of 50%, while the rate without stem cell transplantation or new treatment was 43%. Overall survival was 61%. In patients achieving minimal residual disease-negative remission, stem cell transplantation for consolidation was not observed to provide an additional benefit in 12-month survival rates. These results indicate that obe-cel may provide a robust remission and reduce the need for transplantation.

In conclusion, this FDA approval raises hopes that safer and more effective alternatives can be developed in CAR T-cell therapy. Obe-cel may offer new hope, particularly for patients with relapsed/refractory ALL, through its low toxicity and high response rates.